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Received 4 September 2006; received in revised form 27 December 2006; accepted 4 January 2007; Available online 12 March 2007AbstractObjective: Local recurrence remains a major problem in the treatment of malignant pleural mesothelioma. The aim of the underlying study
was to establish a standardised local recurrence model in rats which enables to study different intrapleural therapies. Materials and methods:
Fifty microlitre containing 1  106 cells of a syngeneic rat malignant mesothelioma cell line (II-45), established frommesothelioma in Fischer 344
rats exposed to asbestos, were inoculated subpleurally via a left-sided thoracotomy. Tumour size was assessed 6 days later and the tumour nodule
completely resected. Evaluation of recurrence at the resection site was performed after 10 days (n = 6) and 6 days (n = 6). The recurrent nodule
was histopathologically confirmed. In a second experiment, this new recurrence model was evaluated for the effect of intrapleural therapy with
different agents: 4 ml of cisplatin-solution (100 mg2/kg BW), cisplatin combined with the fibrin-based sealant VivostatW, 4 ml taurolidine 2%,
repeated injection of 1 mg of the chemokine CCL-19 at the tumour site and 4 ml povidone-iodine in a dilution 1:10. In a control group, the chest
cavity was filled with 4 ml 0.9% NaCl. The primary endpoint was the extent of tumour recurrence. Results: Six days after inoculation, all animals
presented a standardised tumour nodule at the injection site of a mean diameter of 5.1 (0.8) mm. Evaluation of the recurrence after 10 days
showed a relapse directly at the resection site, but additional tumour nodules on the ipsi- and contralateral chest wall were found and
histologically confirmed. The animals that were sacrificed 6 days after resection of the tumour nodule showed a recurrence only at the resection
site with no macroscopic or microscopic evidence of other tumour. Resection of the tumour nodule combined with intrapleural application of the
different agents lead to clear reduction of recurrence. The strongest effect was observed after intrapleural application of cisplatin-VivostatW
with significant decrease of the longest, widest and thickest diameter of the recurrence. Conclusions: With this new recurrence model for
investigation of malignant pleural mesothelioma in rats, we were able to investigate new intrapleural therapies after pneumonectomy. The
intrapleural application of cisplatin-VivostatW significantly reduced the extent of local recurrence.
# 2007 European Association for Cardio-Thoracic Surgery. Published by Elsevier B.V. All rights reserved.
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Malignant pleural mesothelioma (MPM) is an aggressive
tumour arising from the mesothelial lining of the pleural
cavity. The incidence of MPM increased during the last 60
years, and the peak for Europe is expected between 2015 and
2020, with 250,000 predicted deaths in the next 40 years [1].
Multimodality treatment with induction chemotherapy,
extrapleural pneumonectomy (EPP) and postoperative radio-
therapy currently offers a median survival of 23 months [2].
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doi:10.1016/j.ejcts.2007.01.047time to recurrence of 16months. Therefore, new therapeutic
strategies to improve local tumour control are demanded.
Intracavitary therapies such as intrapleural chemotherapy
with cisplatin [3,4], immune therapy [5] and gene therapy [6]
provide the advantage of easy accessibility of the large
surface of the pleura and the possibility to reduce systemic
side effects by increasing the desired local effect.
We were able to demonstrate sustained higher platinum
concentrations in the chest wall tissue while reducing
systemic levels by combination of cisplatin with a surgical
sealant (VivostatW) for intrapleural treatment in comparison
to application of cisplatin alone in a rat mesothelioma model
[7]. Based on the model used for this study, first described by
Kucharczuk et al. [8], representing the clinical situation of
invasive tumour growth of MPM after intrapleural injection of
a syngeneic mesothelioma cell line, we wanted to develop a
new model of local recurrence. This new model wasurgery. Published by Elsevier B.V. All rights reserved.
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resectable tumour and to target the problem of local
recurrence in mesothelioma patients.
With the help of this model, various intrapleural therapies
with chemotherapeutic agents as well as cytotoxic substances
were investigated. The application of taurolidine and povi-
done—iodine (PVP-I) showed cytotoxic effects on human and
rat mesothelioma cell lines in vitro (I. Opitz et al., in press).
Both substancesareused inclinicalpracticewithout important
side effects: taurolidine, a derivate of the amino acid taurine,
as broad spectrum antibiotic, and PVP-I as an antiseptic.
EBV-induced molecule 1 ligand chemokine (ELC/CCL19), a
chemokine expressed in T-cell zones of spleen and lymph
nodes, is a chemokine with proven anti-tumour efficacy by
chemoattracting dendritic cells and T cells to achieve anti-
cancer immunity. A significant reduction of tumour volume
was already demonstrated after intratumoral and intranodal
injections in a murine lung cancer model [9], so that we
included this substance as immunomodulatory arm beside the
chemotherapeutic and cytotoxic treatment groups.
The objective of the underlying study was to establish a
new recurrencemodel for malignant pleural mesothelioma in
the immune competent rat in order to prove the hypothesis
that intrapleural therapy after tumour resection reduces the
extent of recurrence.2. Materials and methods
2.1. Animals and housing
Male Fischer 344 rats weighing 250—300 mg (Harlan, The
Netherlands) were used. The animals were kept in the rodent
facility of the University Hospital Zurich under veterinary
supervision with at least 10 days acclimation period before
the experiments. They had free access to standard laboratory
rat chow and water, and were housed in designated rodent-
storage modules in a temperature-controlled room with a
12:12 h light—dark circle. They received human care in
compliance with the European Convention on Animal Care,
and the study was approved by the local veterinary
committee.
2.2. Cell line
A syngeneic malignant mesothelioma cell line (II-45)
cultured from experimental asbestos-exposed peritoneal
mesothelioma in ratswas used [10]. The cell linewas originally
adonation fromtheMDAndersonCancerCenter, theUniversity
of Texas. Cells were cultured in RPMI medium supplemented
with 10% fetal calf serum and a 1% solution of penicillin and
streptomycin. For tumour implantation, a cell suspension of
50 ml containing 1  106 cells was prepared after labelling the
cells with the fluorescein derivate 5- and 6-carboxyfluorescein
diacetate succinimidyl ester (CFSE) (Sigma, Buchs, Switzer-
land) following a standard procedure [11].
2.3. Anaesthesia
After induction of anaesthesia in an isofluran chamber,
oro-tracheal intubation was performed using a 16 gaugepolyethylene angiocatheter which was introduced by the use
of a laryngoscope. The catheter was connected to a standard
rodent ventilator (Harvard Apparatus, Inc., Model 683,
Germany). Ventilation was performedwith mixture of oxygen
and isofluran (0.5—2%, Forene, Abbott, Switzerland). A tidal
volume of 10 ml/kg was used with a respiratory rate of 75/
min and a PEEP of3 cm H2O. During surgery, the animal was
placed on a warming pad and ophthalmic ointment instillated
for prevention of corneal dessication. For postoperative
analgesia, a subcutaneous injection of 12 mg paracetamol
plus buprenorphin 0.1 mg/kg BW was performed.
2.4. Study design and surgery
2.4.1. Recurrence model
Under general anaesthesia, a tumour cell suspension of
50 ml containing 1  106 cells was inoculated with a thin
needle under the parietal pleura via a small left-sided
thoracotomy in the fifth intercostal space. The chest wall
muscles were reapproximated with 4/0 Vicryl running suture,
and the skin was closed with a 3/0 Vicryl running suture. After
extubation, the animals were observed for 2—4 h and then
returned to their cages. Six days later, thoracotomy was
performed and the size of the tumour nodule at the injection
site was assessed with a slide calliper and thereafter
macroscopically completely resected. Evaluation of recur-
rence at the resection site was performed after sacrifice of
the animal in the first group after 10 days (n = 6) and in a
second group after 6 days (n = 6). The recurrent tumour was
histopathologically confirmed.
2.4.2. Intrapleural treatment
The recurrence model was further evaluated for inves-
tigation of intrapleural treatment. Six days after tumour cell
inoculation as described, the tumour nodule was resected
and a left-sided pneumonectomy was performed with the
help of an operating microscope (magnification 16; Zeiss,
Jena, Germany). The mediastinal pleura was dissected
around the pulmonary hilum while preserving the phrenic
nerve. The left main stem bronchus, the pulmonary artery
and both pulmonary veins were dissected and ligated.
Afterwards, a pleural abrasio was performed by scrubbing
the parietal pleural with an abrader (electro-surgical tip
cleaner, SurgisiteW, Johnson&Johnson). This imitates the
procedure of extrapleural pneumonectomy in humans, as
complete dissection of the parietal pleura in rats is
technically not feasible. The pleural cavity was filled with
the different study substances in a randomised fashion:1. Four millilitre of cisplatin-solution (100 mg/m2): 3 mg/kg
BW corresponding to 1.85 ml of a solution of 10 mg/2 ml
cisplatin in a 280 g rat; 1.85 ml cisplatin was mixed with
2.15 ml 0.9% sodium chloride and filled in the chest cavity.2. Four millilitre cisplatin-VivostatW: VivostatW (Vivolution,
Denmark) is a commercialised surgical fibrin sealant. Fibrin
was obtained and prepared for application as a carrier for
cisplatin (100 mg/m2) as previously described [7].3. Four millilitre of 2% taurolidine (=TaurolinW, Geistlich,
Wohlhusen, Switzerland).4. Fifty microlitre of 1 mg DPBS resuspended recombinant
human CCL19/MIP-3 beta (R&D Systems, Minneapolis,
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PVPUSA) injected at the resection site, repetition of
transthoracic injections on days 3 and 5.5. Four millilitre of 0.77% PVP-I (=BraunolW, Braun Medica-
lAG, Sempach, Switzerland) in a 1:10 dilution.6. Control group (4 ml 0.9% sodium chloride).
Six days after treatment, the animals were sacrificed and
the whole chest wall was dissected for analysis. Two animals
were treated with VivostatW alone as a control for the effect
of fibrin on the tumour.
2.5. Data analysis
The primary endpoint was the extent of tumour
recurrence. The whole thoracic wall was excised and the
longest and widest diameters were assessed with a tape
measure. The macroscopic tumour limits were confirmed by
biopsy specimens taken at both ends and analysed by
fluorescence microscopy by one of the investigators blinded
to the treatment (S.A.). As a third dimension, the thickness of
recurrence wasmicroscopically measured in HE section taken
at the thickest diameter of the tumour nodule by a
pathologist blinded to treatment (P.V.). Necrosis of the
tumour was assessed qualitatively. Contralateral chest walls
were histologically analysed in case of macroscopic suspicion
of tumour.
The secondary endpoints were interleukin-1b (IL-1b),
interleukin-6 (IL-6) and tumour necrosis factor-a (TNF-a)
present either in the cell culture supernatant of lipopoly-
saccharide (LPS)-activated splenocytes or directly detected
in lysate of the tumour tissue at the time point of autopsy.
Splenocytes were isolated using standard procedure
[11,12] co-cultivated at 1  106 cells/ml of mononuclear
cells in complete RPMI medium or RPMI containing 5 mg/ml
LPS from E. coli, Serotype 055:B5 (Sigma, Buchs, Switzer-
land) for 2 days. Supernatant was collected and frozen at
80 8C until assessment. To prepare tumour lysates, glass-
on-glass pestle homogenisation of frozen biopsy specimens
was performed in a ratio of 150 mg tissue/ml (w/v) in ice-
cold DPBS containing a protease cocktail inhibitor (Sigma,
Buchs, Switzerland). After 5 min centrifugation at
14,000 rpm, supernatant was further diluted in ELISA
blocking buffer to a final 3.75 mg/100 ml and loaded in
duplicate on ELISA plates. The ELISA kits used for cytokine
determination were rat IL-6 (R&D Duoset Systems, Minnea-
polis, USA), rat TNF-a (R&D Duoset Systems, Minneapolis,
USA) and rat IL-1( (R&D Duoset Systems, Minneapolis, USA)
according to the manufactures’ protocol.
Sample size calculation was performed with the help of
the Windows program called ‘nQuery Advisor’ Elasthoff,
1995. Statistical analysis was carried out using the softwarele 1
parison of the length, width and thickness of tumour recurrence
Control
(n = 6)
Cisplatin-VivostatW
(n = 7)
Cisplatin
(n = 7)
gth (mean  S.D.) 25.3 (6.3) 13.9 (3.9) 14.6 (5.
th (mean  S.D.) 15.5 (1.8) 4.86 (1.68) 9.4 (5)
kness (mean  S.D.) 5.7 (2.7) 1.61 (.077) 1.5 (0.
-I: povidone-iodine; ANOVA analysis was performed.package SPSS for Windows, version 12.0 SPSS Inc. Data is
given in mean and standard deviation. Data was log
transformed if necessary to reach approximately normally
distributed data before performing ANOVA to compare all the
groups. For post hoc analysis comparisons between the
groups, Bonferroni correction was applied. Differences were
considered to be significant if P-values were smaller than
0.05.3. Results
3.1. Establishment of the tumour model
Six days after tumour cell inoculation, all animals
presented a tumour nodule at the injection site of a mean
diameter of 5.1 (0.8) mm which was macroscopically
completely resected. In the first group, autopsy 10 days
after resection of the tumour nodule revealed not only
recurrent tumour at the resection site but also further
tumour nodule spread over the ipsi- and controlateral chest
wall, which was histologically confirmed. When autopsy was
performed 6 days after resection of the tumour nodule, local
recurrence was observed at the resection site with no
macroscopic or microscopic evidence of other tumour. The
histological evaluation showed a malignant pleural mesothe-
lioma with a sarcomatous growth pattern.
3.2. Intrapleural treatment
In the second part, animals underwent tumour inoculation
and resection of the tumour nodule after 6 days and a
pneumonectomy was performed, followed by intrapleural
treatment according to the randomisation. Perioperative
death occurred in two animals. Tumour recurred at the
resection site in all animals. In the untreated animals and
those treated with VivostatW alone, further tumour mani-
festation in the mediastinum and on the diaphragm was
observed at autopsy. Comparison of the thickness, length and
width of tumour recurrence between those control groups
and the treatment groups showed a significant reduction in
all three diameters (Table 1). The most important effect was
observed after intrapleural application of cisplatin-Vivos-
tatW, which had a significant impact on the extent of tumour
recurrence (Fig. 1), as had cisplatin-solution on the thickness
and the length of the tumour. The application of taurolidine
lead to strong reduction of the tumour recurrence, but only
the tumour length tended to be significantly influenced
(P = 0.06). After treatment with PVP-I and CCL-19, the size of
recurrence was reduced but in a not statistically significant
manner (Figs. 2—4).-solution Taurolidine
(n = 7)
CCL-19
(n = 7)
PVP-I
(n = 6)
P-value
7) 15.6 (5.2) 16.7 (3.7) 21.3 (8.7) 0.006
10.3 (4.1) 11.4 (2.8) 16.5 (7.2) 0.0001
6) 3.5 (1.6) 4.7 (2.5) 4.5 (1.4) 0.001
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Fig. 1. Comparison of the tumour recurrence after intrapleural treatment
with cisplatin-VivostatW (upper part) to the untreated control.
Fig. 3. Box plots of length of tumour recurrence. PVP-I: povidone-iodine;
Cisplatin-S.: cisplatin-solution; Cisplatin-V.: cisplatin-VivostatW. Post hoc ana-
lysis was performed with Bonferroni corrections. *P = 0.02; §P = 0.01.Histological examination revealed necrotic formation in
all the tumours of cisplatin-VivostatW or cisplatin-solution-
treated animals and in six out of seven animals treated with
taurolidine. In the other groups, only 50% of the animals
presented necrotic tumour (Fig. 5).Fig. 2. Box plots of the thickness of tumour recurrence. PVP-I: povidone-
iodine; Cisplatin-S.: cisplatin-solution; Cisplatin-V.: cisplatin-VivostatW. Post
hoc analysis was performed with Bonferroni corrections. *P = 0.009; §P = 0.005.To investigate the influence of the different treatments on
cytokine production, spleens were removed to obtain
mononuclear cell cultures that were cultured 48 h in the
presence or absence of 5 mg/ml LPS. As a control, lower
concentrations of the different cytokines were detected in
supernatants of mononuclear cell culture without LPS
stimulation (data not shown). Cytokine determination
showed significant reduction (P = 0.03) of the IL-6 levels in
splenocyte culture supernatant after stimulation with LPS in
the treatment groups in comparison to the control group and
in comparison to the animals treated with VivostatW alone
(Fig. 6). A similar decrease was observed concerning theFig. 4. Box plots of the width of tumour recurrence. PVP-I: povidone-iodine;
Cisplatin-S.: cisplatin-solution; Cisplatin-V.: cisplatin-VivostatW. Post hoc ana-
lysis was performed with Bonferroni corrections. *P = 0.001.
I. Opitz et al. / European Journal of Cardio-thoracic Surgery 31 (2007) 772—778776
Fig. 5. Comparison of necrotic tissue at the site of recurrence after treatment
with cisplatin-VivostatW (upper part) in comparison to tumour tissue in the
control group.
Fig. 6. IL-6 levels (pg/ml) in the splenocytes 48 h after LPS stimulation. PVP-I:
povidone-iodine; Cisplatin-S.: cisplatin-solution; Cisplatin-V.: cisplatin-Vivos-
tatW. Post hoc analysis was performed after log transforming data. *P = 0.03.levels of IL-1b and TNF-a in the spleens, but was not
significant. Analysis of the cytokines in the tumour tissue
showed no trends of changes in IL-6, IL-1b and TNF-a
between the treatment groups and the control group.4. Discussion
We were able to successfully establish a model of local
recurrence of malignant pleural mesothelioma in the immune
competent rat. Although several models with subcutaneous,
but also orthotopic intrapleural injections of xenografted
human mesothelioma cell lines exist [13,14], this does not
reflect the clinical situation of patients with pleural-based
disease with an intact immune system. The described model
allows now to investigate therapy effects on the develop-
ment of tumour recurrence in a standardised manner while
reflecting the clinical situation of tumour resection in an
immune competent animal.
Local intrapleural treatment is an attractive treatment
option for patients with MPM, as this disease primarily
remains confined to the pleural cavity, and can be
administered as adjuvant strategy after EPP in order to
attack minimal residual disease. The instillation of each
substance tested lead to reduction of local recurrence. The
application of the DNA-damaging agent cisplatin combined to
the fibrin-based sealant VivostatW caused the strongest and
most significant reduction of tumour recurrence in all
dimensions (length, width and thickness) and tumour was
necrotic in all cases. The application of cisplatin-solution
gave similar results but was not significantly better than all
the other groups concerning the width of the tumour
recurrence. In a previous study, we could demonstrate that
platinum concentration in the chest wall remains signifi-
cantly higher up to 1 week when cisplatin is combined with
VivostatW [7]. The effect of heterologous fibrin alone in the
sense of an unspecific immune response against the tumour
was excluded, as the behaviour of tumour recurrence was the
same in the groups receiving VivostatW alone as in the control
group. Thus, the advantage of cisplatin-VivostatW is probably
due to an optimised pharmacodynamic with higher local
tissue concentration whilst systemic concentrations and
therefore systemic side effects are reduced. This hypothesis
can be confirmed by a higher nephrotoxicity after instillation
of cisplatin-solution [7]. Clinical phase I and phase II studies
investigating the application of intrapleural cisplatin-che-
motherapy with concentrations up to 250 mg/m2 following
pleurectomy and decortication or EPP [3,4,15] reported
treatment-related complication rates up to 47% [3,15] and
treatment-related deaths [16] are described. As the
procedure of EPP represents a challenging procedure itself
with morbidity rates up to 60% [17], reduction of systemic
side effects caused by cisplatin are desired. The combination
with this fibrin-based sealant may be a solution for this
problem; therefore, further investigation is planned includ-
ing higher concentrations of cisplatin-VivostatW.
Taurolidine might also be an attractive therapy option as
important—although only nearly significant—decrease of
the recurrence size was observed after taurolidine treat-
ment in the underlying study. As taurolidine lead in vitro to
a mesothelioma cell-specific response (I. Opitz et al., in
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it represents an interesting drug for this multimodal
approach.
The effect of taurolidine has been widely described for
antineoplastic treatment in ovarian cancer, lung cancer,
melanoma, glioblastoma and colon cancer in vitro and in vivo
[19,20]. Currently, an European multicentre study is ongoing
for the investigation of adjuvant intraperitoneal irrigation
with taurolidine after resection of colon cancer. Its effect is
related to induction of apoptosis [20] and inhibition of
growth-promoting cytokines as IL-1 or other anti-inflamma-
tory cytokines as TNF-a [21] which have a stimulating effect
on tumour growth [22]. Both of them are also described as
key cytokines known to play a role in mesothelioma [23]. In
our study, we observed lower levels of IL-1b and TNF-a
produced by LPS-stimulated splenocytes in all treatment
groups in comparison to the control group at the time point of
autopsy. The same decrease occurred with IL-6 levels.
Mesothelioma is reportedly an IL-6-secreting tumour [23,24].
Furthermore, IL-6 was described as a stimulating growth
factor in the development of mesothelioma [25]. The
significant lower levels of IL-6 after cisplatin-based treat-
ment may reflect the destruction of not only mesothelioma
cells but also of locally present immuno-regulatory cells, so
that 5 days after treatment, we observed a reduced IL-6
production in the splenocytes after LPS stimulation. This
might also explain the minor decrease of cytokine levels by
the other substances reflecting the less aggressive mechan-
ism of action. Wewere not able to detect these differences in
cytokine levels in the tumour tissue. Most likely, the biopsy
specimens of the tumour were too small to determine
cytokine production by the tumour-infiltrating lymphocytes.
Main part of the tumour had to be preserved for histological
examination.
The intratumoral injection of the chemokine CCL-19
decreased the size of recurrence, but differences to the
control group were not significant. Although this agent led to
significant reduction of tumour volume in a murine lung
cancer model [9], we were not able to reproduce this in our
model. A possible explanation for this might be the use of a
human form of the chemokine CCL-19 in our rat model,
although it was already successfully used in other rat models
[12] or an inaccurate, transthoracic technique of the
repeated intratumoral injection for only 1 week. For future
application, production of gene-modified dendritic cells
expressing the chemokine is under investigation.
Only the application of PVP-I seemed to have practically
no influence on tumour recurrence, but in this group
particular problems to distinguish between tumour and
neighbouring inflammatory tissue were described by the
pathologist, so that data for this group may not be
representative. In order to elucidate this problem, we
performed immunohistochemistry. Despite detection of the
CFSE labelled tumour cells in biopsy specimens by fluores-
cence microscopy, we failed to immunostain the CFSE dye
with anti-FITC antibodies. This may be due to the fast division
rate of II-45 cells and the subsequent dilution of the dye to
undetectable levels for immunohistochemistry. For future
projects, we have now stable transfectants of the II-45 cell
line with a luciferase expressing vector allowing better
distinction between tumour and surrounding tissue, as well asdaily and quantitative monitoring of treatment success by
bioluminescent imaging.5. Conclusion
With this new recurrence model for investigation of
MPM in rats, we were able to investigate new intrapleural
therapies. The intrapleural application of cisplatin-VivostatW
significantly reduced the extent of local recurrence. Further
investigation of combination treatments based on cisplatin-
VivostatW are planned.Acknowledgement
This study was funded by the ‘Zu¨rcher Krebsliga’ and
‘Sonnenwiesestiftung’. We thank Birgit Oberreiter and Vlasta
Strohmeier for assistance during the operations, Prof. B. Ris
for delivering the cell line and Daniel Demierre for technical
assistance.
References
[1] Robinson BWS, Lake RA. Advances in malignant mesothelioma. N Engl J
Med 2005;353(15):1591—603.
[2] Weder W, Kestenholz P, Taverna C, Bodis S, Lardinois D, Jerman M, Stahel
RA. Neoadjuvant chemotherapy followed by extrapleural pneumonect-
omy in malignant pleural mesothelioma. J Clin Oncol 2004;22(17):
3451—7.
[3] Richards WG, Zellos L, Bueno R, Jaklitsch MT, Janne PA, Chirieac LR, Yeap
BY, Dekkers RJ, Hartigan PM, Capalbo L, Sugarbaker DJ. Phase I to II study of
pleurectomy/decortication and intraoperative intracavitary hyperthermic
cisplatin lavage for mesothelioma. J Clin Oncol 2006;24(10):1561—7.
[4] Rusch V, Saltz L, Venkatraman E, Ginsberg R, McCormack P, Burt M,
Markman M, Kelsen D. A phase II trial of pleurectomy/decortication
followed by intrapleural and systemic chemotherapy for malignant
pleural mesothelioma. J Clin Oncol 1994;12(6):1156—62.
[5] Monnet I, Breau J-L, Moro D, Lena H, Eymard J-C, Menard O, Vuillez J-P,
Chokri M, Romet-Lemonne J-L, Lopez M. Intrapleural infusion of activated
macrophages and {gamma}-interferon in malignant pleural mesothe-
lioma*: a phase II study. Chest 2002;121(6):1921—7.
[6] Sterman DH, Recio A, Vachani A, Sun J, Cheung L, DeLong P, Amin KM,
Litzky LA, Wilson JM, Kaiser LR, Albelda SM. Long-term follow-up of
patients with malignant pleural mesothelioma receiving high-dose ade-
novirus herpes simplex thymidine kinase/ganciclovir suicide gene ther-
apy. Clin Cancer Res 2005;11(20):7444—53.
[7] Lardinois D, Jung FJ, Opitz I, Rentsch K, Latkoczy C, Vuong V, Varga Z,
Rousson V, Gunther D, Bodis S. Intrapleural topical application of cisplatin
with the surgical carrier Vivostat increases the local drug concentration in
an immune-competent rat model with malignant pleuromesothelioma. J
Thorac Cardiovasc Surg 2006;131(3):697.
[8] Kucharczuk JC, Elshami AA, Zhang HB, Smythe WR, Hwang HC, Tomlinson
JS, Amin KM, Litzky LA, Albelda SM, Kaiser LR. Pleural-based mesothe-
lioma in immune competent rats: a model to study adenoviral gene
transfer. Ann Thorac Surg 1995;60(3):593—7.
[9] Hillinger S, Yang S-C, Zhu L, Huang M, Duckett R, Atianzar K, Batra RK,
Strieter RM, Dubinett SM, Sharma S. EBV-induced molecule 1 ligand
chemokine (ELC/CCL19) promotes IFN-{gamma}-dependent antitumor
responses in a lung cancer model. J Immunol 2003;171(12):6457—65.
[10] Craighead JE, Akley NJ, Gould LB, Libbus BL. Characteristics of tumors
and tumor cells cultured from experimental asbestos-induced mesothe-
liomas in rats. Am J Pathol 1987;129(3):448—62.
[11] Coligan JE, Bierer BE, Margulies DH, Shevach EM, Strober W. Curr
Protocols Immunol. New York: John Wiley and Sons; 2006.
[12] Phillips R, Ager A. Activation of pertussis toxin-sensitive CXCL12 (SDF-1)
receptors mediates transendothelial migration of T lymphocytes across
lymph node high endothelial cells. Eur J Immunol 2002;32(3):837—47.
I. Opitz et al. / European Journal of Cardio-thoracic Surgery 31 (2007) 772—778778[13] Prewitt TW, Lubensky IA, Pogrebniak HW, Pass HI. Orthotopic implanta-
tion of mesothelioma in the pneumonectomized immune-deficient rat: a
model for innovative therapies. Int J Cancer 1993;55(5):877—80.
[14] Kane AB. Animal models of malignant mesothelioma. Inhal Toxicol
2006;18(12):1001—4.
[15] de Bree E, van Ruth S, Baas P, Rutgers EJT, van Zandwijk N, Witkamp AJ,
Zoetmulder FAN. Cytoreductive surgery and intraoperative hyperthermic
intrathoracic chemotherapy in patients with malignant pleural mesothe-
lioma or pleural metastases of thymoma. Chest 2002;121(2):480—7.
[16] Lu C, Perez-Soler R, Piperdi B, Walsh GL, Swisher SG, Smythe WR, Shin HJ,
Ro JY, Feng L, Truong M, Yalamanchili A, Lopez-Berestein G, Hong WK,
Khokhar AR, Shin DM. Phase II study of a liposome-entrapped cisplatin
analog (L-NDDP) administered intrapleurally and pathologic response
rates in patients with malignant pleural mesothelioma. J Clin Oncol
2005;23(15):3495—501.
[17] Opitz I, Kestenholz P, Lardinois D, Muller M, Rousson V, Schneiter D, Stahel
R, Weder W. Incidence and management of complications after neoad-
juvant chemotherapy followed by extrapleural pneumonectomy for
malignant pleural mesothelioma. Eur J Cardiothorac Surg 2006;29(4):
579.
[18] Jacobi CA, Menenakos C, Braumann C. Taurolidine—a new drug with anti-
tumor and anti-angiogenic effects. Anticancer Drugs 2005;16(9):917—21.
[19] Opitz I, Ven Der Veen HC, Braumann C, Ablassmaier B, Fuhrer K, Jacobi
CA. The influence of adhesion prophylactic substances and taurolidine/
heparin on local recurrence and intraperitoneal tumor growth after
laparoscopic-assisted bowel resection of colon carcinoma in a rat model.
Surg Endosc 2003;17(7):1098—104.
[20] Calabresi P, Goulette FA, Darnowski JW. Taurolidine: cytotoxic and
mechanistic evaluation of a novel antineoplastic agent. Cancer Res
2001;61(18):6816—21.
[21] Jacobi CA, Wenger F, Sabat R, Volk T, Ordemann J, Muller JM. The impact
of laparoscopy with carbon dioxide versus helium on immunologic func-
tion and tumor growth in a rat model. Dig Surg 1998;15(2):110—6.
[22] Lanfrancone L, Boraschi D, Ghiara P, Falini B, Grignani F, Peri G, Mantovani
A, Pelicci PG. Human peritoneal mesothelial cells produce many cyto-
kines (granulocyte colony-stimulating factor [CSF], granulocyte-mono-
cyte-CSF, macrophage-CSF, interleukin-1 [IL-1], and IL-6) and are
activated and stimulated to grow by IL-1. Blood 1992;80(11):2835—42.
[23] Bielefeldt-Ohmann H, Jarnicki AG, Fitzpatrick DR. Molecular pathobiol-
ogy and immunology of malignant mesothelioma. J Pathol 1996;178(4):
369—78.
[24] Schmitter D, Lauber B, Fagg B, Stahel RA. Hematopoietic growth
factors secreted by seven human pleural mesothelioma cell lines:interleukin-6 production as a common feature. Int J Cancer
1992;51(2):296—301.
[25] Adachi Y, Aoki C, Yoshio-Hoshino N, Takayama K, Curiel DT, Nishimoto N.
Interleukin-6 induces both cell growth and VEGF production in malignant
mesotheliomas. Int J Cancer 2006;119(6):1303—11.
Appendix A. Conference discussion
Dr S. Aharinejad (Vienna, Austria): What was the source of the cells?
Where did you get the cells from?
Dr Opitz: The cell line is a donation from the MD Anderson Cancer Center in
Texas. The cell line was established by culturing cells from peritoneal
mesothelioma in rats exposed to asbestos. This cell line was used for subpleural
inoculation.
Dr Aharinejad: So these are rat tumour cells?
Dr Opitz: This is a syngeneic rat mesothelioma cell line.
Dr Aharinejad: And the last question, how many cells did you inject?
Dr Opitz: We injected a million cells in a volume of 50 microlitres.
Dr R. Schmid (Bern, Switzerland): Why didn’t you do an I.V. control with
the cisplatin, to see if the local treatment was really better than the systemic
treatment?
Dr Opitz: This has already been investigated in clinical studies by
comparing intrapleural cisplatin to intravenous cisplatin. They observed in
these clinical phase I and phase II trials that the level of cisplatin was
significantly higher in the pleural fluid when used as intrapleural therapy than
after intravenous therapy. As we wanted to target the problem of local
recurrence, we concentrated on this more effective local treatment.
Dr D. Wood (Seattle, USA): In that regard, you learned that not only did
your model successfully result in a local recurrence but also in contralateral
disease. I wonder about systemic disease, and that might direct us back to
Ralph’s question of systemic rather than local therapy for a model that looks
like it’s a timing issue of whether you catch it when it’s just local versus
systemic. Is your model specific enough as a local recurrencemodel rather than
potentially a systemic recurrence model that you might look at systemic
therapies, as Dr Schmid was talking about?
Dr Opitz: There is surely also the possibility to study systemic therapy in
this model, but we were interested in the problem of local recurrence after
tumour resection that occurs in the clinical situation earlier than distant
metastases. But still it is also possible to investigate systemic therapy or
combined local and systemic therapy.
